243 related articles for article (PubMed ID: 38308674)
1. Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS?
Valent P; Akin C; Arock M
Curr Allergy Asthma Rep; 2024 Mar; 24(3):133-141. PubMed ID: 38308674
[TBL] [Abstract][Full Text] [Related]
2. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.
Valent P; Bonadonna P; Hartmann K; Broesby-Olsen S; Brockow K; Butterfield JH; Triggiani M; Lyons JJ; Oude Elberink JNG; Arock M; Metcalfe DD; Akin C
Int Arch Allergy Immunol; 2019; 180(1):44-51. PubMed ID: 31256161
[TBL] [Abstract][Full Text] [Related]
3. [Tryptase: A practical guide for the physician].
Lobbes H; Reynaud Q; Mainbourg S; Lega JC; Durieu I; Durupt S
Rev Med Interne; 2020 Nov; 41(11):748-755. PubMed ID: 32712042
[TBL] [Abstract][Full Text] [Related]
4. Hymenoptera Allergy and Mast Cell Activation Syndromes.
Bonadonna P; Bonifacio M; Lombardo C; Zanotti R
Curr Allergy Asthma Rep; 2016 Jan; 16(1):5. PubMed ID: 26714690
[TBL] [Abstract][Full Text] [Related]
5. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α.
Ravi A; Butterfield J; Weiler CR
J Allergy Clin Immunol Pract; 2014; 2(6):775-8. PubMed ID: 25439370
[TBL] [Abstract][Full Text] [Related]
6. Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders.
Zaghmout T; Maclachlan L; Bedi N; Gülen T
J Allergy Clin Immunol Pract; 2024 Mar; 12(3):753-761. PubMed ID: 38056692
[TBL] [Abstract][Full Text] [Related]
7. Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology.
Giannetti MP; Akin C; Hufdhi R; Hamilton MJ; Weller E; van Anrooij B; Lyons JJ; Hornick JL; Pinkus G; Castells M; Pozdnyakova O
J Allergy Clin Immunol; 2021 Apr; 147(4):1497-1501.e1. PubMed ID: 33248113
[TBL] [Abstract][Full Text] [Related]
8. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals.
González-de-Olano D; Navarro-Navarro P; Muñoz-González JI; Sánchez-Muñoz L; Henriques A; de-Andrés-Martín A; Peralta-Arjonilla D; Mayado A; Jara-Acevedo M; García-Montero AC; Orfao A; Álvarez-Twose I
Allergy; 2024 Mar; 79(3):711-723. PubMed ID: 37818990
[TBL] [Abstract][Full Text] [Related]
9. Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction.
Valent P; Akin C
J Allergy Clin Immunol Pract; 2019 Apr; 7(4):1109-1114. PubMed ID: 30961836
[TBL] [Abstract][Full Text] [Related]
10. Using the Right Criteria for MCAS.
Gulen T
Curr Allergy Asthma Rep; 2024 Feb; 24(2):39-51. PubMed ID: 38243020
[TBL] [Abstract][Full Text] [Related]
11. Mast Cell Activation Syndrome.
Frieri M
Clin Rev Allergy Immunol; 2018 Jun; 54(3):353-365. PubMed ID: 25944644
[TBL] [Abstract][Full Text] [Related]
12. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.
Valent P; Hartmann K; Bonadonna P; Niedoszytko M; Triggiani M; Arock M; Brockow K
Int Arch Allergy Immunol; 2022; 183(7):693-705. PubMed ID: 35605594
[TBL] [Abstract][Full Text] [Related]
13. A Challenge for Allergologist: Application of Allergy Diagnostic Methods in Mast Cell Disorders.
Romantowski J; Górska A; Niedoszytko M; Gulen T; Gruchała-Niedoszytko M; Nedoszytko B; Lange M; Brockow K; Arock M; Akin C; Valent P
Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33535634
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine.
Valent P; Akin C; Nedoszytko B; Bonadonna P; Hartmann K; Niedoszytko M; Brockow K; Siebenhaar F; Triggiani M; Arock M; Romantowski J; Górska A; Schwartz LB; Metcalfe DD
Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261124
[TBL] [Abstract][Full Text] [Related]
15. Increased Excretion of Mast Cell Mediator Metabolites During Mast Cell Activation Syndrome.
Butterfield JH
J Allergy Clin Immunol Pract; 2023 Aug; 11(8):2542-2546. PubMed ID: 36863614
[TBL] [Abstract][Full Text] [Related]
16. Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
Muñoz-González JI; García-Montero AC; Orfao A; Álvarez-Twose I
Ann Allergy Asthma Immunol; 2021 Oct; 127(4):427-434. PubMed ID: 34298172
[TBL] [Abstract][Full Text] [Related]
17. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal.
Valent P; Akin C; Arock M; Brockow K; Butterfield JH; Carter MC; Castells M; Escribano L; Hartmann K; Lieberman P; Nedoszytko B; Orfao A; Schwartz LB; Sotlar K; Sperr WR; Triggiani M; Valenta R; Horny HP; Metcalfe DD
Int Arch Allergy Immunol; 2012; 157(3):215-25. PubMed ID: 22041891
[TBL] [Abstract][Full Text] [Related]
18. Management of Mediator Symptoms, Allergy, and Anaphylaxis in Mastocytosis.
Gulen T
Immunol Allergy Clin North Am; 2023 Nov; 43(4):681-698. PubMed ID: 37758406
[TBL] [Abstract][Full Text] [Related]
19. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
20. Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.
Matito A; Escribese MM; Longo N; Mayorga C; Luengo-Sánchez O; Pérez-Gordo M; Matheu V; Labrador-Horrillo M; Pascal M; Seoane-Reula ME;
J Investig Allergol Clin Immunol; 2021 Dec; 31(6):461-470. PubMed ID: 33541851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
